Trials / Conditions / Unresectable Paraganglioma
Unresectable Paraganglioma
5 registered clinical trials studyying Unresectable Paraganglioma.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Active Not Recruiting | Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Ne NCT04394858 | National Cancer Institute (NCI) | Phase 2 |
| Withdrawn | Radioactive Drug (177Lu-DOTATATE) for the Treatment of Locally Advanced, Metastatic, or Unresectable Rare Endo NCT04106843 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic NCT02721732 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Cabozantinib S-malate in Treating Patients With Metastatic Pheochromocytomas or Paragangliomas That Cannot Be NCT02302833 | M.D. Anderson Cancer Center | Phase 2 |
| Completed | Dovitinib in Neuroendocrine Tumors NCT01635907 | Abramson Cancer Center at Penn Medicine | Phase 2 |